ReviewFrontiers in immunology2026
Deciphering the mechanistic involvement of PANoptosis in FC-MDD comorbidity through the gut-brain axis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional constipation (FC) is closely associated with major depressive disorder (MDD). Patients suffering from chronic constipation often develop psychological issues such as anxiety and low mood due to persistent physical discomfort. These emotional disturbances can become prolonged, ultimately progressing into depression. Patients with major depressive disorder frequently experience gastrointestinal dysfunction, including diarrhea and constipation, with constipation symptoms being particularly persistent. The co-occurrence of these conditions is extremely common in clinical practice and severely compromises patients' physical and mental health. PANoptosis represents a pan-inflammatory form of programmed cell death (PCD). Unlike single-pathway PCD, it simultaneously engages pyroptosis, apoptosis, and necrosis within a single cell by recruiting key molecules from multiple PCD pathways, accompanied by massive inflammatory cytokine release. This review analyzes the panoptosis mechanism in FC-MDD based on bidirectional regulation of the gut-brain axis, offering a novel perspective on elucidating its comorbidity pathology. However, current evidence primarily stems from animal models and mechanistic studies, with limited direct clinical data on FC-MDD. Future efforts should validate these findings in clinical populations, explore the specific roles of PANoptosome complex subtypes, develop targeted intervention strategies, and advance basic research toward clinical translation to identify more precise therapeutic targets for FC-MDD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.